0001104659-23-115795.txt : 20231108 0001104659-23-115795.hdr.sgml : 20231108 20231108170321 ACCESSION NUMBER: 0001104659-23-115795 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231108 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231108 DATE AS OF CHANGE: 20231108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jaguar Health, Inc. CENTRAL INDEX KEY: 0001585608 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36714 FILM NUMBER: 231389085 BUSINESS ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-371-8300 MAIL ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Jaguar Animal Health, Inc. DATE OF NAME CHANGE: 20130830 8-K 1 tm2330239d1_8k.htm FORM 8-K
false 0001585608 0001585608 2023-11-08 2023-11-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 8, 2023 

 

 

 

JAGUAR HEALTH, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 001-36714 46-2956775
(State or other jurisdiction of
incorporation)		 (Commission File Number) (IRS Employer Identification No.)

 

200 Pine Street, Suite 400

San Francisco, California

 94104
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (415) 371-8300 

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, Par Value $0.0001 Per Share JAGX The Nasdaq Capital Market

 

 

 

 

 

 

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

On November 8, 2023, Jaguar Health, Inc. (the “Company”) received a notification letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had been granted an additional 180 days, or until May 6, 2024, to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market with the exception of the bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period.

 

As previously disclosed by the Company in a Current Report on Form 8-K filed on May 12, 2023, the Company received a notification letter from the Staff notifying the Company that, because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive business days, the Company no longer met the Minimum Bid Price Requirement.

 

The Company intends to continue actively monitoring the bid price for its common stock between now and May 6, 2024 and will consider available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement.

 

This Current Report on Form 8-K contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including the statement that the Company will consider available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement. The words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. While the Company believes its plans, intentions and expectations reflected in those forward-looking statements are reasonable, these plans, intentions or expectations may not be achieved. The Company’s actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements. For information about the factors that could cause such differences, please refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, including the information discussed under the captions “Item 1 Business,” “Item 1A. Risk Factors” and “Item 7 Management’s Discussion and Analysis of Financial Condition and Results of Operations,” as well as the Company’s various other filings with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The Company assumes no obligation to update any forward-looking statement.

 

Item 7.01. Regulation FD Disclosure.

 

On November 8, 2023, the Company issued a press release announcing Nasdaq’s notification letter granting the Company a second 180-day compliance period to meet the Minimum Bid Price Requirement, a copy of which is furnished as Exhibit 99.1.

 

The information in Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference into any of the Company’s filings under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)  Exhibit

 

Exhibit No.   Description
99.1   Press Release, dated November 8, 2023.
104   Cover Page Interactive Data File (embedded within the inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  JAGUAR HEALTH, INC.
   
  By: /s/ Lisa A. Conte
    Name: Lisa A. Conte
    Title: President and Chief Executive Officer

 

Date: November 8, 2023

 

 

 

 EX-99.1 2 tm2330239d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

Jaguar Health Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq’s Bid Price Rule

 

San Francisco, CA (November 8, 2023): Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on November 8, 2023 the Company received formal notice that the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC has granted Jaguar an additional 180-day grace period, through May 6, 2024, to regain compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. The Staff noted that the Company meets all other applicable requirements for initial and continued listing on The Nasdaq Capital Market. To evidence compliance, the Company must report a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days on or before May 6, 2024.

 

“We are pleased to have obtained additional time from Nasdaq to evidence compliance with the bid price requirement,” Lisa Conte, Jaguar's president and CEO, said. “Our paramount near-term clinical activity is our Phase 3 pivotal OnTarget trial of Mytesi for the follow-on indication of the preventative treatment of cancer therapy-related diarrhea, an indication we also refer to as chemotherapy-induced overactive bowel (CIOB) – which includes symptoms such as chronic debilitating diarrhea, GI urgency, and GI incontinence. Top line results from this pivotal study are expected before Thanksgiving.”

 

Jaguar is supporting investigator-initiated and investigator IND proof-of-concept studies of crofelemer for the rare disease indications of microvillus inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal failure in the US, EU and Middle East/North Africa (MENA) regions, with results expected before the end of 2023 and in 2024. In accordance with the guidelines of specific EU countries, published data from such clinical investigations could support reimbursed early patient access to crofelemer for SBS or MVID for these debilitating conditions.

 

Crofelemer has been granted Orphan Drug Designation (ODD) by the FDA and the European Medicines Agency (EMA) for both MVID and SBS with intestinal failure. The ODD programs in the U.S. and European Union qualify sponsors to receive potential incentives to develop therapies for the diagnosis, prevention, or treatment of rare diseases or conditions.

 

About the Jaguar Health Family of Companies

 

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo Pharmaceuticals’ crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

 

 

 

 

 

For more information about:

 

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

 

Visit Jaguar on LinkedIn: https://www.linkedin.com/company/jaguar-health/

Visit Jaguar on X: https://twitter.com/Jaguar_Health

Visit Jaguar on Instagram: https://www.instagram.com/jaguarhealthcommunity/

 

Forward-Looking Statements

 

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that top line results of the OnTarget study will be available before Thanksgiving 2023. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

 

Source: Jaguar Health, Inc.

 

Contact:

hello@jaguar.health

 

Jaguar-JAGX

 

 

 

 EX-101.SCH 3 jagx-20231108.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 jagx-20231108_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 jagx-20231108_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2330239d1_ex99-1img001.jpg GRAPHIC begin 644 tm2330239d1_ex99-1img001.jpg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htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 08, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 08, 2023
Entity File Number 001-36714
Entity Registrant Name JAGUAR HEALTH, INC.
Entity Central Index Key 0001585608
Entity Tax Identification Number 46-2956775
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 200 Pine Street
Entity Address, Address Line Two Suite 400
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94104
City Area Code 415
Local Phone Number 371-8300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, Par Value $0.0001 Per Share
Trading Symbol JAGX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2330239d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001585608 2023-11-08 2023-11-08 iso4217:USD shares iso4217:USD shares false 0001585608 8-K 2023-11-08 JAGUAR HEALTH, INC. DE 001-36714 46-2956775 200 Pine Street Suite 400 San Francisco CA 94104 415 371-8300 false false false false false Common Stock, Par Value $0.0001 Per Share JAGX NASDAQ EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://jaguaranimalhealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports jagx-20231108.xsd jagx-20231108_lab.xml jagx-20231108_pre.xml tm2330239d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2330239d1_8k.htm": { "nsprefix": "jagx", "nsuri": "http://jaguaranimalhealth.com/20231108", "dts": { "schema": { "local": [ "jagx-20231108.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "jagx-20231108_lab.xml" ] }, "presentationLink": { "local": [ "jagx-20231108_pre.xml" ] }, "inline": { "local": [ "tm2330239d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://jaguaranimalhealth.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-08", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2330239d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-08", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2330239d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-23-115795-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-115795-xbrl.zip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end